[Outcome of treatment with surgical resection of the remaining tumor after modified M-VAC treatment for advanced urothelial carcinoma].
Hinyokika Kiyo
; 51(3): 155-8, 2005 Mar.
Article
in Ja
| MEDLINE
| ID: mdl-15852667
ABSTRACT
We retrospectively evaluated the effect of the surgical resection of the remaining tumor after modified M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) (m-M-VAC) treatment for locally advanced or metastatic urothelial carcinoma. In m-M-VAC therapy, methotrexate and vinblastine on 15 and 22 days were omitted from the classical M-VAC to avoid the discontinuation and the dose reduction, and duration of 1 course was shortened to 21 days from 28 days of the classical M-VAC. Seven patients with locally invasive or metastatic carcinoma of the renal pelvis, ureter, and bladder, 6 males and 1 female, with a median age 64.1 years, ranging from 49 to 77 years received m-M-VAC chemotherapy without severe side effects. In all patients, the residual viable carcinoma was completely resected and they achieved complete remission. The median survival time was 20 months (range, 7 to 61). Five of these 7 patients were still alive. Two patients had no recurrence and achieved long-term survival (survival duration; 61 and 39 months). Although further studies and long-term follow up are required, these results suggest that patients who present with locally advanced or metastatic urothelial carcinoma may benefit from surgical resection after m-M-VAC.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Transitional Cell
/
Antineoplastic Combined Chemotherapy Protocols
/
Urologic Neoplasms
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
Ja
Journal:
Hinyokika Kiyo
Year:
2005
Type:
Article